Evidence map›Paper›PMID 42502508›Full record

ArticleMolecular therapy. Advances2026

Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector for

Victoria Duback, Shalu S Kharkwal, Vasily Vagin, Kerrie Paterson, Alicia Sabbio, Joohwan Kim, Amey Gaikwad, Jesse Green, Brian Dolinski, Kelan Hlavaty and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Victoria DubackSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Shalu S KharkwalSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Vasily VaginSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Kerrie PatersonSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Alicia SabbioSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Joohwan KimSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Amey GaikwadSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Jesse GreenSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Brian DolinskiSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Kelan HlavatySana Biotechnology, Inc., Cambridge, MA 02139, USA.
Garrett ZippSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Shannon JoyceSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Abigail KoppesNortheastern University, Department of Chemical Engineering, Boston, MA 02115, USA.
Bindu VargheseSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Kyle TrudeauSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Jagesh ShahSana Biotechnology, Inc., Cambridge, MA 02139, USA.
Terry FrySana Biotechnology, Inc., Cambridge, MA 02139, USA.
Kutlu G ElpekSana Biotechnology, Inc., Cambridge, MA 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given challenges with access, manufacturability, and the requirement for lymphodepletion with autologous chimeric antigen receptor (CAR)-T cell therapy, a promising alternative is

Indexed as

cancerCAR-Tclearancegene therapyin vivolentivirusmouse modelpharmacodynamicspharmacokineticsviral vector

Identifiers

PMID42502508
PMCPMC13400396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.